Clinical Trial Update: Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione [Phase 4]

View source ↗

Summary

Phase 4 trial comparing exenatide with sitagliptin on 24-hour average glucose in patients with Type 2 Diabetes Mellitus on metformin or a thiazolidinedione.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BYETTA (Exenatide)
• Januvia (sitagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2011-01-20